Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Market News
The Mayne Pharma (ASX:MYX) share price leaps almost 8% higher
Share Fallers
Why IDP Education, IRESS, Mosaic Brands, & Mayne Pharma are dropping lower
Share Market News
Mayne Pharma share price on watch as earnings slump 27%
Healthcare Shares
The ASX stocks that could enjoy a consensus earnings upgrade this reporting season
How to invest
Here's how to start investing with $5k
Share Market News
These 2 ASX medical shares are on the rise after major announcements
Share Gainers
Why Electro Optic Systems, Mayne Pharma, Tyro, & WAM Leaders are racing higher
Share Market News
Mayne Pharma share price on watch after announcing major Novast Laboratories agreement
Healthcare Shares
Why the Mayne Pharma share price is climbing today
Share Market News
These 5 ASX shares saw the biggest losses last week
⏸️ TMF AMP
ASX 200 Weekly Wrap: ASX back in the green
Share Fallers
These were the worst performers on the ASX 200 last week
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
